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Multivariable logistic and linear 
regression models for identification 
of clinically useful biomarkers 
for osteoarthritis
Yulia Liem1, Andrew Judge1, John Kirwan2, Khadija ourradi1, Yunfei Li1 & 
Mohammed Sharif1*
osteoarthritis (oA) is the most common chronic degenerative joint disease which causes substantial 
joint pain, deformity and loss of activities of daily living. Currently, there are over 500 million 
oA cases worldwide, and there is an urgent need to identify biomarkers for early detection, and 
monitoring disease progression in patients without obvious radiographic damage to the joint. We 
have used regression modelling to describe the association of 19 of the currently available biomarkers 
(predictors) with key radiographic and clinical features of oA (outcomes) in one of the largest and 
best characterised OA cohort (NIH Osteoarthritis Initiative). We demonstrate that of the 19 currently 
available biomarkers only 4 (serum Coll2-1 NO2, CS846, COMP and urinary CTXII) were consistently 
associated with established radiographic and/or clinical features of oA. these biomarkers are 
independent of one another and provide additional predictive power over, and above established 
predictors of OA such as age, gender, BMI and race. We also show that that urinary CTXII had the 
strongest and consistent associations with clinical symptoms of oA as well as radiographic evidence 
of joint damage. Accordingly, urinary CTXII may aid in early diagnosis of OA in symptomatic patients 
without radiographic evidence of oA.
Osteoarthritis (OA) is a common chronic degenerative disease affecting the knees, hips, hands and spine. Recent 
data suggests that 40% of men and 47% of women over 25 are at risk of OA and over 250 million people are 
affected  worldwide1,2. In the UK over 3 million GP consultations and 115,000 hospital admissions/year are due 
to OA and it costs the UK economy approximately £3.2 billion in lost working days  alone3. OA is an increasing 
burden on the NHS and other providers of healthcare in the western countries. OA is a multifactorial disease of 
unknown aetiology. The major risk factors for developing OA are age, gender, obesity, injuries and joint shape. 
The disease develops slowly over the years and is characterized by progressive loss of articular cartilage, subchon-
dral bone remodelling, osteophytes formation and variable synovial inflammation. Currently diagnosis is based 
on symptoms, and usually confirmed with X-ray at late-stage disease when there is already irreparable damage 
to the joints. Other imaging methods such as Magnetic Resonance Imaging (MRI) and Dual-energy X-ray 
absorptiometry (DXA) may be used for early diagnosis and monitoring OA but widespread routine use of these 
imaging techniques is limited by their availability and/or costs. Although MRI can be used early in OA and can 
be predictive of radiographic change as it can directly visualise all articular  tissues4,5, it is not cost-effective and 
is time  consuming6. Dual-energy X-ray absorptiometry (DXA) may be used to measure bone mineral density 
(BMD) at specific regions of interest (ROI) in OA as increased BMD is known to be associated with an increase 
in Kellgren and Lawrence (K&L) grade, sub-chondral sclerosis and minimum joint space width (JSW)7. A major 
limitation of DXA is that the position of the knee must be identical in serial readings for accurate data. Also, 
soft tissue swelling may prevent the full extension of the knee preventing the DXA image from being within 
the  ROI8,9. Therefore, there is an urgent need for identification of suitable biomarkers for early detection and 
monitoring OA.
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During the last three decades we and others have demonstrated that serum and urinary levels of biomarkers 
can provide a way of monitoring OA and some of these biomarkers (mediators and products of intra-artricular 
tissue degradation, attempted repair and inflammation) are clearly associated with biological and pathological 
processes in knee  OA10–13. Yet none of the biomarkers have been shown to be sufficiently specific or sensitive 
for early diagnosis and/or monitoring of individual at-risk patients, and/or predict the course of disease with 
 time14. Many research programmes aim to develop pharmaceutical treatments for OA that will alter the course 
of the disease, but these programmes are significantly hampered by the lack of good biochemical methods for 
early detection and monitoring of disease progression. The slow progress in the field is largely due to a lack of 
suitable cohorts and robust analytical tools for discovery of OA-specific biomarkers. The availability of clinical, 
biomarker and radiographic data from the National Institute of Health (NIH) Osteoarthritis Initiative (OAI) 
multi-centre prospective 96 months observational cohort provides an opportunity to identify clinically useful 
biomarkers for knee OA.
Methods
All data were obtained from the Osteoarthritis Initiative (OAI) database (https ://www.nia.nih.gov/resea rch/
resou rce/osteo arthr itis-initi ative -oai). OAI is a longitudinal cohort study sponsored by the National Institute of 
Health (NIH) to understand how to prevent and treat knee  OA15. The study recruited a total of 4,491 men and 
women aged from 45 to 79, with, or at risk of symptomatic femoral-tibial knee OA (supplementary Table 1). The 
study included all ethnic minorities but mainly focused on African Americans. Men and women with inflam-
matory arthritis (mainly rheumatoid arthritis, RA), contraindication to MRI and bilateral end-stage knee OA 
were excluded from the study. 4,491 subjects were followed up annually for 10 years and demographic, clinical, 
radiographic, blood and urine samples were collected at baseline and at yearly follow up. The details of the study 
protocols and all informed patient consent documentation were reviewed and approved by the OAI-NIH (https ://
oai.epi-ucsf.org/datar eleas e/docs/Study Desig nProt ocol.pdf)15. Our study is a retrospective study using publicly 
available data from a subset of 600 OAI patients who were K&L grade 1 or more and had biochemical markers 
measured at baseline, 12 and 24 months in blood and/or urine (Fig. 1).
Biomarkers. All available biomarker data at baseline, 12 and 24 months from the subsets of 600 patients 
(Fig. 1) were extracted from the OAI data set. The biomarkers that were analysed in serum included C-propep-
tide of type II collagen (CPII), oligomeric matrix protein (COMP), N-propeptide of collagen IIA (PIIANP), 
chondroitin sulphate 846 (CS846), C-terminal cross-linked telopeptide of type I collagen (CTXI), hyaluronic 
acid (HA), matrix metalloproteinase-3 (MMP-3), types I and II collagen marker degradation markers (C1,2C, 
C2C), the nitrated form of α-helical region of type II collagen (Coll2-1 NO2) and the cross-linked N-telopeptide 
of type I collagen (NTXI). Biomarkers analysed in urine were C-terminal crosslinked telopeptide of type II 
collagen (CTXII), and alpha and beta isomerised versions of the CTXI (CTXIα `and CTXIβ). The protocol for 
collection, processing of the blood samples, selection and quantification of the biomarkers had been described 
 elsewhere15.
Radiographic features of oA. The radiographic features of OA investigated included joint space narrow-
ing (JSN) or joint space width (JSW), osteophytes and Kellgren and Lawrence (K&L) grade which indicate the 
overall radiographic severity of knee OA. These radiographic data from baseline and all follow up visits from 600 
patients who have biomarker measurements were obtained from the OAI Website.
clinical features of oA. The clinical features of OA investigated included joint pain and stiffness. We 
downloaded the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC 
index (set of standardized questionnaires) is commonly used by health professionals to evaluate the condition of 
patients with OA of the knee, and includes pain, stiffness, and physical functioning of the joints. The Knee injury 
and Osteoarthritis Outcome Score (KOOS) is an extension of the WOMAC index but is considered to be more 
sensitive and responsive than the WOMAC in younger or more active  patients16,17. Since pain is the main symp-
tom of OA, we focused on WOMAC and KOOS pain in this study. WOMAC and KOOS pain scores are available 
from baseline and follow up visits which were downloaded from the OAI website. Baseline demographic infor-
mation such as age, race, gender and BMI were also obtained.
Data cleaning and descriptive statistics. Data cleaning for all biochemical markers, radiographic and 
clinical measurements were performed using Stata 15.1. The mean, standard deviation and the frequencies for 
each variable were then calculated. The biomarker (continuous data) were examined and any outliers were iden-
tified and removed by using the cut off range available from Kraus et al.18. The dataset contains information on 
outcome (radiographic and clinical variables) for both left and right knees. The biomarkers are collected at a 
person level and are not knee specific. We chose to do a patient-based analysis using the maximum K&L grade 
for the worst knee for each patient.
Statistical analysis. Spearman correlation was used to evaluate multicollinearity of 19 biochemical bio-
markers. Serum NTXI, urinary NTXI, urinary CTXI alpha and urinary CTXI beta were removed due to strong 
correlation with each other in the final model. Urinary Coll2-1 NO2 was also removed in the final model as it 
had the highest missing data (n = 261).
Logistic and linear regression models were used to describe the associations of predictors with the outcomes. 
The exposures (predictors of interest) are the biomarkers. Outcomes of interest are radiographic and clinical OA 
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variables. The outcome radiographic and clinical variables were defined as K&L grade ≥ 2, JSN medial and lateral 
side OARSI grade of ≥ 1, osteophytes OARSI of ≥ 1, and WOMAC pain and stiffness score ≥ 3, JSW, KOOS pain 
and symptoms score. Logistic regression models were fitted for the following outcomes: K&L grade, JSN (medial 
and lateral), WOMAC (pain and stiffness) and osteophytes (medial and lateral). Odd ratios were used to describe 
the biomarkers of having an increase of 1 unit per exposure (outcome variables). Linear regression models were 
fitted for the outcome variables: JSW, KOOS pain and symptoms as the data was continuous. All models were 
analysed using univariate model first, where it described the association of each individual biomarker with 
outcome without adjusting for age, body mass index (BMI), gender and race. Fractional polynomial regression 
modelling was used to assess the assumption of linearity of continuous biomarkers with outcome. A full multi-
variable model was fitted to evaluate the association of all 19 biomarkers with the outcomes and adjusting for age, 
BMI, gender, and race. To demonstrate the discriminatory ability of a combination of biomarkers on predicting 
the radiographic and clinical outcomes, area under the curve (AUC) and receiver operator characteristic curves 
(ROC) was performed. Forest plots were used to provide a visualise display of the association the biomarkers 
with the outcome variables. The unit of measurements of some of the biomarkers were adjusted to the power of 
10, 100, 1,000 and logarithmically transformed to plots the graphs.
The statistical analysis described above for baseline data were repeated for K&L grades 12 months and 
24 months to check for consistency of the strength of associations across time points. Analysis of the outcome 
variables JSN, JSW and osteophytes, WOMAC pain and KOOS pain scores were carried out on baseline bio-
marker data only. In all multivariable analyses between clinical symptoms and biomarkers the data was adjusted 
for overall radiographic severity (K&L grade). P values of less than 0.05 was considered as statistically significant.
Results
Logistic regression models. Spearman correlation was used to check for the collinearity of the predictors 
(biomarkers) (supplementary Table 2). The results showed that serum CTXI was highly correlated with serum 
NTXI (r = 0.6108), urinary NTXI (r = 0.7474), urinary CTXIα (r = 0.8210) and CTXIβ (r = 0.8230) while urine 
NTXI was positively correlated with urinary CTXIα (r = 0.8661) and CTXIβ (r = 0.8586). Therefore, in the mul-
tivariable final regression model all predictors showing collinearity (urinary C2C, CTXIα, CTXIβ, NTXI and 
serum NTXI) were removed from the model and data adjusted for age, gender, BMI and race.
In the univariable model baseline K&L grade was significantly associated with serum C2C, CPII, Coll2-1 
NO2, HA and urinary CTXII, while the 12 months K&L grades correlated with serum CTXI and HA only. At 
24 months K&L grades was associated with serum HA, urinary C2C and urinary CTXII (supplementary Table 3). 
The correlation between urinary CTXII and K&L grade were essentially similar at baseline and 24 months 
although the actual observed odd ratio was slightly stronger at 24 months (supplementary Table 3). In the 
adjusted multivariate model where, age, race, BMI and gender were controlled for, serum Coll2-1 NO2, COMP 
and urinary CTXII were associated with baseline K&L grade, whereas the 12 months K&L grade showed that 
only serum CTXI and NTXI were significant (supplementary Table 4). In the final multivariable model, only 
urinary CTXII had strong association with baseline and 24 months K&L grade (supplementary Table 5). As the 
pattern of associations of the this biomarker with K&L grades were broadly similar across all three models at 
baseline and 24 months, the rest of the analysis for WOMAC (pain and stiffness) JSN (medial and lateral), JSW, 
osteophytes (medial and lateral) modelling were carried out using baseline data only.
The results of univariable and multivariable logistic regression models are summarised in a Forest plot (Fig. 2). 
Of the 19 biomarkers only a handful of the markers were significant and that urinary CTXII had the strongest 
association compared to all other biomarkers for both radiographic and clinical outcome variables (Fig. 2). In 
multivariate analysis, urinary CTXII repeatedly showed positive associations with all four outcome measures used 
in this study; K&L grade 1.06 (95% CI 1.023–1.099), WOMAC pain 1.01 (95% CI 1.002–1.025), JSN medial 1.01 
(95% CI 1.001–1.031) and osteophytes lateral 1.02 (95% CI 1.006–1.035). Serum COMP is negatively associated 
with KL grade and WOMAC pain. Serum COMP is negatively associated with KL grade and WOMAC pain but 
not JSN lateral. The results of all the biomarkers that were found to have a significant association with either 
radiographic and/or clinical outcomes of OA are summarised in Table 1.
Urinary CTXII consistently showed strong significant associations with radiographic and clinical outcomes. 
The observed associations of urinary CTXII and serum Coll2-1 NO2, CS846, COMP with radiographic and 
clinical outcomes variables significantly improved when these 4 biomarkers were considered as a group (Fig. 3, 
ROC curves). For evaluation of the discriminatory diagnostic ability of the biomarkers AUC values were cal-
culated. The combined AUC for the 4 biomarkers for K&L grade was 0.69 but when age, gender, BMI and race 
were included as well, it improved to 0.74 which suggest that the model was a good discriminator in predicting 
biomarkers with the outcome. Similarly, other radiographic and clinical variable showed improved AUC results 
between the 4 biomarkers combined and the multivariate model. For the 4 combined biomarkers, the AUC values 
for WOMAC pain, WOMAC stiffness, JSN medial, JSN lateral, osteophytes medial and osteophytes lateral were 
0.57, 0.58, 0.58, 0.65, 0.61, 0.60 respectively. Whereas, the multivariate model AUC for WOMAC pain, WOMAC 
stiffness, JSN medial, JSN lateral, osteophytes medial and osteophytes lateral were 0.68, 0.67, 0.69, 0.75, 0.72 and 
0.72 respectively (Fig. 3).
Linear regression models. Linear regression was used to determine the association of the biomarkers 
with JSW, KOOS pain and symptoms. The repeated measures showed that serum HA (p: < 0.01), urinary C2C (p: 
0.04) and CTXII (p: < 0.01) are associated with JSW in the univariate model. However, in the multivariate model, 
serum C2C, CPII, COMP, HA and urinary CTXII showed significant association (p: < 0.01 for all 5 biomarkers) 
with JSW (Table 2). Urinary CTXII was associated with both KOOS pain and symptoms across the different 
models; univariate and multivariate (Fig. 4).
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In both multivariate logistic and linear regression of clinical symptoms (KOOS pain and symptoms, WOMAC 
pain and stiffness) and biomarkers data was adjusted for the radiographic severity (K&L grades). The results 
showed no differences in the AUC values for WOMAC pain and WOMAC stiffness. For WOMAC pain AUC 
unadjusted and adjusted were 0.67 and 0.68 respectively. For WOMAC stiffness unadjusted and adjusted AUC 
were 0.66 and 0.67 respectively. Similarly, when adjusting for the radiographic severity in the multivariate linear 
regression (KOOS pain and KOOS symptoms), the results showed that only urinary CTXII was significant. the 
values allowing for radiographic severity were − 0.0775037 (− 0.1439451, − 0.0110622), p: 0.022 [coefficient, 
95% CI, and p values]. The results were very similar to the previous multivariate linear regression model without 
adjusting for radiographic severity (Table 2).
Discussion
OA is the most common joint disease and early diagnosis and monitoring of progression of the disease using 
biomarkers have gained considerable attention in recent years. However, despite extensive investigation, there 
are currently no biomarkers approved by the FDA for diagnosis and monitoring of OA due to limited specificity 
and sensitivity. In this study, we have used one of the largest publicly available datasets to identify potentially 
clinically useful biomarkers for OA. Our data show that of the 19 biomarkers only 4 (serum Coll2-1 NO2, CS846, 
COMP and urinary CTXII) were consistently associated with established radiographic and/or clinical features 
of OA (Table 1). Our results also show that urinary CTXII had the strongest and most consistent associations 
with radiographic and clinical features of OA. These biomarkers are independent of one another and provide 
additional predictive power over and above established demographic predictors of OA such as age, gender, BMI 
and race. Therefore, we suggest that these 4 biomarkers are the most promising biomarkers for investigating of 
OA and may be considered clinically useful particularly urinary CTXII. Identification of these 4 biomarkers as 
clinically useful markers will help to focus future OA studies and is a crucial step in the realization of individual-
ized care for patients with OA.
The results show that urinary CTXII is significantly associated with K&L grades, osteophytes scores on the 
medial site, WOMAC (stiffness), JSW, and KOOS (pain). Urinary CTXII has been investigated extensively and 
shown to be elevated in OA patients with radiographic  OA19,20, associated with pain, K&L grades and other 
radiographic features of OA, and predicts radiographic pain  progression21–23. The Joseph et al.24 and Kraus et al.25 
studies used data from the OAI cohort but in both studies the presence of bilateral OA could have influenced 
the results since patient reported pain on physical function and pain score were  used24,25. In this study, we have 
chosen the worst affected knee and patient-based measurements of urinary CTXII and other biomarkers are 
therefore more likely to be a better reflection of the disease process in individual patients. Moreover, the Joseph 
et al. study was focused on correlation of the biomarkers with MRI T2 measures of cartilage matrix degenera-
tion suggesting that biomarkers (serum MMP3, serum HA, serum COMP) are sensitive to cartilage changes, 
while the Kraus et al. study investigated short-term (2 years) prognostic value of 18 of the 19  biomarkers24,25. 
The latter study demonstrated that several of these biomarkers (serum HA, NTXI, CTXI and urinary CTXII, 
C2C, NTXI, CTXI alpha CTXI beta) could predict worsening of pain and radiographic OA over 2  years24. Our 
study is uniquely designed to identify biomarkers that would be of clinical value for early decision making about 
diagnosis have led to identification of different biomarker combination (serum Coll2-1 NO2, CS846, COMP and 
urinary CTXII) than those identified by the latter studies using the same cohort.
In our earlier studies of urinary CTXII we found that CTXII was significantly higher in the progressors 
(defined as either a reduction of the tibiofemoral joint space width by ≥ 2 mm or total knee replacement surgery 
for either knee occurring during the 5-year follow-up) and remained high throughout the study  period12. Moreo-
ver, there was a rapid rise in CTXII during the first 2 years of follow-up in the progressors indicating a more 
aggressive course of the disease in these patients at an early  stage12. The results of the current study are broadly 
Table 1.  Multivariate logistic regression model for biomarkers showing associations with either radiographic 
and/or clinical features of OA. Age, BMI, gender, and race were adjusted for in the model. Statistically 
significant data are shown in bold.
Outcome
sColl2-1 NO2 sCS846 sCOMP uCTXII
OR (95%) p-value OR (95%) p-value OR (95%) p-value OR (95%) p-value
KL grade 1.1316 (1.0289, 1.2445) 0.011
0.9972 (0.9913, 
1.0032) 0.364
0.9988 (0.9977, 
0.9999) 0.036
1.0607 (1.0231, 
1.0996) 0.001
WOMAC pain 1.0012 (0.9614, 1.0427) 0.954
1.0032 (0.9999, 
1.0065) 0.056
0.9991 (0.9984, 
0.9997) 0.005
1.0138 (1.0023, 
1.0253) 0.018
WOMAC Stiff-
ness
1.0137 (0.9710, 
1.0584) 0.535
1.0048 (1.0011, 
1.0085) 0.011
1.0005 (0.9999, 
1.0012) 0.110
1.0072 (0.9954, 
1.0192) 0.232
JSN medial 0.9967 (0.9511, 1.0446) 0.892
1.0014 (0.9976, 
1.0053) 0.466
1.0002 (0.9994, 
1.001) 0.699
1.0164 (1.0013, 
1.0318) 0.033
JSN lateral 1.0704 (0.9967, 1.1495) 0.062
0.9909 (0.9829, 
0.9989) 0.026
1.0015 (1.0004, 
1.0027) 0.008
0.9918 (0.9692, 
1.015) 0.484
Osteophytes 
medial
0.9860 (0.9168, 
1.0605) 0.705
0.9957 (0.9906, 
1.0007) 0.092
0.9998 (0.9986, 
1.001) 0.699
1.023 (0.9965, 
1.0502) 0.090
Osteophytes 
lateral
1.0561 (1.0059, 
1.1089) 0.028
1.0007 (0.9971, 
1.0042) 0.716
0.9997 (0.999, 
1.0004) 0.431
1.0205 (1.0061, 
1.0351) 0.005
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in agreement with previous studies, and additionally suggest that unlike any of the other current biomarkers, 
urinary CTXII is associated with the main radiographic features of OA (JSN, osteophytes and K&L grade) as 
well as clinical outcome variables WOMAC stiffness and a knee specific measure of OA pain (KOOS score). In 
the multivariable analyses between these clinical symptoms and the biomarker adjusting for radiographic sever-
ity gave almost identical AUC values suggesting that the association observed are independent of radiographic 
severity as measured by K&L grade. Another new observation reported in this study is the association of urinary 
CTXII with JSN on the medial compartment of the knee joint. This is important since both cartilage degrada-
tion and bone changes usually occur on the medial side  first26,27 and therefore CTXII may be a marker of early 
cartilage loss as well as bone remodelling.
It is generally accepted that there is a high discordance between clinical and radiographic knee  OA28–30. 
Thus, only about 50% of the patients with radiographic knee OA have knee  pain29, and even levels of disability 
experienced by patients appear to correlate better with their age and psychological involvement than with their 
radiographic  scores28,30. Despite the widely reported discordance between radiographic damage and pain, we 
show here that urinary CTXII reflects knee specific pain in OA as we well as radiographic evidence of joint 
Figure 1.  Study design: Total number of subjects for each biomarker, radiographic and clinical variables. 
*Urinary Coll 2-1 NO2 was removed due to large number of missing data.
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Univariate
Biomarkers (n = 300–
600)
JSW KOOS pain KOOS symptoms
Coeffecient (95% CI) p value Coefficient (95% CI) p value Coefficient (95% CI) p value
Serum C1,2C − 0.0002 (− 0.0070, 0.0066) 0.960 0.0079 (− 0.0634, 0.0791) 0.828 0.015 (− 0.0469, 0.077) 0.634
Serum C2C − 0.0016 (− 0.0036, 0.0004) 0.116
− 0.0101 (− 0.0314, 
0.0112) 0.353
− 0.0009 (− 0.0195, 
0.0176) 0.922
Serum CPII 0.00013 (− 0.0001, 0.0005) 0.393
− 0.001 (− 0.0043, 
0.0022) 0.539
− 0.0004 (− 0.0033, 
0.0024) 0.769
Serum PIIANP − 0.00001 (− 0.0002, 0.00013) 0.920
− 0.001 (− 0.0024, 
0.0004) 0.148
− 0.0005 (− 0.0017, 
0.0007) 0.422
Serum Coll2-1 NO2 − 0.00474 (− 0.0237, 0.0143) 0.624
− 0.1811 (− 0.3796, 
0.0173) 0.074
− 0·1424 (− 0.315, 
0.0303) 0.106
Serum CS846 − 0.00025 (− 0.0021, 0.0016) 0.786
− 0.0,104 (− 0.0294, 
0.0086) 0.283
− 0.0138 (− 0.0303, 
0.0028) 0.102
Serum MMP3 − 0.00282 (− 0.0106, 0.0049) 0.473 0.0572 (− 0.0236, 0.1379) 0.165 0.0917 (0.0217, 0.1617) 0.010
Serum CTXI 0.00006 (− 0.0004, 0.00055) 0.787 0.0022 (− 0.0029, 0.0072) 0.399 0.0004 (− 0.004, 0.0048) 0.852
Serum COMP − 0.00189 (− 0.0360, 0.0322) 0.913
0.0,013 (− 0.0023, 
0.0049) 0.480 0.0001 (− 0.003, 0.0032) 0.943
Serum HA − 0.00543 (− 0.0082, − 0.0026) 0.001
− 0.0032 (− 0.0328, 
0.0263) 0.830 0.0113 (− 0.0142, 0.0369) 0.385
Serum NTXI 0.01034 (− 0.0089, 0.0296) 0.292 0.0386 (− 0.1632, 0.2405) 0.707
− 0.0292 (− 0·2047, 
0·1463) 0.744
Urine CTXII − 0.0105 (− 0.0157, − 0.0052) 0.001
− 0.0678 (− 0.1235, − 
0.0120) 0.017
− 0.0730(− 0·1213, − 
0.0247) 0.003
Urine C1,2C 0.08211 (− 0.0084, 0.1726) 0.075
− 0.5382 (− 1.4914, 
0.4151) 0.268
− 0·1075 (− 
0·9360,0·7210) 0.799
Urine C2C − 0.00143 (− 0.0024, − 0.0005) 0.004 0.0025 (− 0.0077, 0.0128) 0.627
− 0.0006 (− 0.0095, 
0.0083) 0.889
Urine NTXI − 0.0006 (− 0.0065, 0.0053) 0.837 0.0083 (− 0.0538, 0.0705) 0.792 0.004 (− 0.0499, 0.058) 0.884
Urine CTX1 alpha − 0.0001 (− 0.0003, 0.00023) 0.742 0.0015 (− 0.0015, 0.0045) 0.325 0.0009 (− 0.0017, 0.0035) 0.501
Urine CTX1 beta 0.00001 (− 0.00004, 0.00008) 0.579
− 0.0001 (− 0.0007, 
0.0006) 0.837
− 0.0001 (− 0.0006, 
0.0005) 0.761
Urine Coll2-1 NO2 0.00023 (− 0.0085, 0.00901) 0.958
− 0.0422 (− 0.1405, 
0.0561) 0.399 0.0224 (− 0.063, 0·1077) 0.607
Urine creatinine 0.01372 (− 0.0055, 0.0329) 0.161 − 0.18 (− 0.382, 0.022) 0.081
− 0.1414 (− 0·3169, 
0.034) 0.114
Multivariate
Biomarkers (n = 580) JSW KOOS pain KOOS symptoms
Serum C1,2C 0.0032 (− 0.0052, 0.0116) 0.456 0.0506 (− 0.0361, 0·1372) 0.252 0.0387 (− 0.0367, 0.1141) 0.314
Serum C2C − 0.0029 (− 0.0054, − 0.0004) 0.023 0.0054 (− 0.0205, 0.0314) 0.681 0.0146 (− 0.008, 0.0372) 0.205
Serum CPII 0.0005 (0.000, 0.0009) 0.033 0.0012 (− 0.0031, 0.0055) 0.597 0.0014 (− 0.0024, 0.0,051) 0.468
Serum PIIANP − 0.0001 (− 0.0002, 0.0001) 0.788
− 0.0005 (− 0.002, 
0.0009) 0.466
− 0.0003 (− 0.0015, 
0.001) 0.658
Serum Coll2-1 NO2 − 0.0102 (− 0.0337, 0.0133) 0.394
− 0·1316 (− 0·3743, 
0·1112) 0.287
− 0·1461 (− 0·3575, 
0.0652) 0.175
Serum CS846 − 0.0004 (− 0.0022, 0.0015) 0.695
− 0.0072 (− 0.0264, 
0.0119) 0.459
− 0.0105 (− 0.0271, 
0.0062) 0.218
Serum MMP3 − 0.0027 (− 0.0116, 0.0063) 0.559 0.0184 (− 0.0739, 0·1106) 0.696 0.0594 (− 0.0209, 0.1397) 0.147
Serum CTXI 0.0003 (− 0.0005, 0.0012) 0.415 0.0034 (− 0.0052, 0.012) 0.438 0.001 (− 0.0065, 0.0085) 0.789
Serum COMP 0.0004 (0.0000, 0.0007) 0.049 0.0015 (− 0.0023, 0.0053) 0.437 − 0.0007 (− 0.004, 0.0026) 0.665
Serum HA − 0.0041 (− 0.0073, − 0.0009) 0.013
− 0.0017 (− 0.0349, 
0.0314) 0.919 0.0057 (− 0.0232, 0.0345) 0.700
Urine CTXII − 0.0122 (− 0.0185, − 0.0058) 0.001
− 0.0862 (− 0.1517, − 
0.0206) 0.010
− 0.0908 (− 0.1478, − 
0.0337) 0.002
Urine C1,2C 0.0892 (− 0.0184, 0·1968) 0.104 − 0.0164 (− 1.1282, 1.0953) 0.977 0·3362 (− 0.6317, 1.3041) 0.495
Urine NTXI 0.0011 (− 0.0098, 0.0119) 0.848 − 0.0016 (− 0.1133, 0.1101) 0.977 0.0294 (− 0.0679, 0.1267) 0.553
Continued
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damage. Therefore, we suggest that urinary CTXII may aid in early diagnosis of OA in symptomatic patients 
without radiographic evidence of OA. Of-course, further studies in patients with symptomatic OA is needed to 
confirm the diagnostic and clinical usefulness of urinary CTXII. In addition, the data reported here are from an 
aging OA cohort, therefore further studies in independent younger cohort, post-traumatic OA and metabolic 
OA are needed to confirm the clinical usefulness of CTXII.
Serum COMP is a pentameric non-collagenous glycoprotein belonging to the heterogeneous family of throm-
bospondin which can bind to collagen type I, II, and IX. It functions as a catalyst in collagen fibril formation and 
many studies have shown that serum COMP is elevated in OA and after knee  injury31,32. Serum COMP has been 
extensively studied by our group and others and shown to have some value as a diagnostic and/or prognostic 
maker of knee  OA32,33. Most of the previous studies investigating serum COMP have shown that serum COMP 
levels reflect structural and metabolic changes in  OA34,35. A few studies that have looked for associations with 
clinical symptoms have shown inconsistent  results36. The data presented here is from one of the largest and best 
characterised cohort of OA patients and shows that serum COMP is associated with two of the main features of 
structural change in OA (JSN and K&L grade) as well as joint pain. The association of serum COMP with struc-
tural damage in OA is easy to explain as it is a marker of cartilage damage, but its association with joint pain is 
not straightforward. Synovium is a likely source of joint pain in OA and since high COMP levels are also found 
in synovium, COMP levels may reflect low-grade synovial inflammation in knee OA. This is consistent with 
data showing elevated serum COMP in patients with RA, a disease characterised by synovial  inflammation37. 
Other investigators have suggested that urinary CTXII and serum COMP reflect the metabolism of type II col-
lagen  fibres38 and are both associated with cartilage degradation. Therefore, serum COMP is one of the better 
biomarkers of OA which reflect structural damage as well as main joint symptom, pain. However, it is worth 
noting that serum COMP is not OA-specific and elevated levels have been reported in other chronic  diseases37,39.
CS846 is a chondroitin sulphate epitope considered to be a marker of aggrecan degradation and elevated 
levels have been reported by many studies following joint  injury40,41. Earlier studies have shown that CS846 was 
almost absent from normal adult cartilage, but increased levels have been reported in  OA42,43 and therefore this 
marker may be considered to have some degree of disease specificity. Serum COMP and CS846 are thought to 
be released following initial damage and activation of repair mechanism and as such may reflect pathological 
increase in turnover of newly formed  matrix44,45. A number of previous studies analysed serum COMP and CS846 
in OA and found the two biomarkers are positively correlated, and when combined the biomarkers gave signifi-
cantly improved AUC values compared to that of the single biomarker for diagnosis of  OA46. Our data show that 
serum CS846 was associated with WOMAC stiffness and JSN and but it was not correlated with serum COMP. 
We suggest that the damage to type II collagen molecule is the key trigger for release and elevated levels of both 
serum COMP and CS846 in OA. This hypothesis would be consistent with our observation that urinary CTXII 
(a specific marker of type II collagen degradation), which is known to be elevated in OA, appear to be a marker 
of both structural damage and symptoms but did not correlate directly with serum COMP or CS846 in this study.
The association of serum COMP and serum CS846 with joint space narrowing on the lateral side was an 
unexpected finding because as markers of cartilage degradation serum levels of both markers were expected 
to correlate with loss of cartilage irrespective of joint sides. One possible explanation is that serum COMP and 
CS846 are derived from different joint compartments including synovium and meniscus and the association 
seen may represent type 1 error.
Coll2-1NO2 is the nitrated form of Coll2-1 peptide (108HRGYPGLDG116) found in the triple helix of the 
type II collagen  molecule47. Unlike the other biomarkers of OA, Coll2-1NO2 is a relative new marker of OA and 
there is only a limited number of studies of this marker compared to CTXII, COMP and CS846. Coll2-1 NO2 
is thought to be produced by stressed chondrocytes following cartilage damage and activation of inflammatory 
 cytokines48. Serum Coll2-1 NO2 is elevated in OA subjects and urinary Coll 2-1 NO2 levels have been reported to 
be associated with global WOMAC score and WOMAC pain and predictive of radiographic knee  OA49. Our data 
showing association of serum Coll2-1 NO2 with osteophytes and K&L grades is therefore broadly in agreement 
with published data and additionally suggest Coll2-1 NO2 is a marker of overall radiographic severity of knee OA.
Our study has identified four clinically useful biomarkers for OA of which only urinary CTXII was consist-
ently correlated with the main radiographic features of OA and symptoms. Identification of these biomarkers 
will help future studies to focus on these markers instead of a long list of markers many which are not associated 
with clinical and/or radiographic features of OA. The AUC for the prediction of individual markers with the 
association of K&L grade ≥ 2 are ranging from 0.4 to 0.6 which means that each individual markers are a poor 
diagnostic discriminatory ability (Supplementary Table 3). However, when the 4 biomarkers are combined 
together adjusted for age, BMI, gender and race, the predictive ability increases to 0.74 (Fig. 3), suggesting that 
Multivariate
Biomarkers (n = 580) JSW KOOS pain KOOS symptoms
Urine creatinine 0.0012 (− 0.0239, 0.0263) 0.925 − 0·1347 (− 0.3937, 0.1243) 0.307
− 0·1139 (− 0.3394, 
0.1115) 0.321
Table 2.  Univariate and multivariate linear regression for JSW, KOOS pain and symptoms. Biomarkers 
are considered as a group in the multivariate regression model and adjusted for age, BMI, gender and race. 
Unit of measurements of some biomarkers (serum C1,2C, COMP, CTXI and urinary CTXII, C1,2C, Coll2-1 
NO2, CTXII alpha and beta) were adjusted to the power of 10, 100, 1,000 and logarithmically transformed. 
Statistically significant data are shown in bold.
8Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11328  | https://doi.org/10.1038/s41598-020-68077-0
www.nature.com/scientificreports/
Figure 2.  Logistic regression for baseline data. Values are odd ratios 95% confidence intervals. Unit of 
measurements of some biomarkers (serum C1,2C, CTXI and urinary CTXII, C1,2C, Coll2-1 NO2, CTXII alpha 
and beta) were adjusted to the power of 10, 100, 1,000 and logarithmically transformed. In the multivariate 
model biomarkers were considered as a group allowing for age, gender, BMI and race.
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a clinically useful biomarker may be created for better specificity and sensitivity for diagnosing and monitoring 
OA. Similar results were obtained when the repeated measures were analysed with worse knee side measure-
ments of JSN medial and lateral side (OARSI score: ≥ 1), WOMAC pain and stiffness (score: ≥ 3) and osteophytes 
in medial and lateral sides (OARSI score: ≥ 1) providing further support to the contention that a combination 
of biomarkers can improve prediction of clinical and radiographic severity of OA. The severity of radiographic, 
clinical features and the demographic data provide a clear evidence that development of OA does not depend 
on a single factor and that a combination of biomarkers may be created to investigate OA  pathology46. Our data 
provided clear evidence for this and is consistent with results of a recent study where the authors showed that 
combining demographic factors, and K&L grade with urinary CTXII significantly improved the AUC for predic-
tion of total joint replacement over a two year  period50.
The strengths of the study included comprehensive in-depth analysis of the largest cohort of patients with a 
wide range of urine and serum biomarkers, and well-defined clinical symptoms and radiographic OA outcomes. 
In this study the biomarkers were measured in serum and urine, presumably reflecting release of the biomark-
ers from all joints (whether symptomatic or asymptomatic) therefore the associations between markers and 
radiographic and/or clinical features of OA in the index joint may be even stronger than that is reported here.
There are several limitations of this study. We had to exclude the urinary Coll2-1 N02 due to missing data, 
and there was collinearity between some of the biomarkers (supplementary Table 2) which meant we had to 
exclude biomarkers from the final adjusted model. Biomarkers are patient level variable, and do not distinguish 
between right and left knees, so we made the decision to choose the worst affect knee for OA outcomes which 
were collected for both sides. The associations observed are cross sectional in nature (data on biomarkers and 
outcomes collected all at baseline), and these findings do not inform as to the predictive validity of biomarkers on 
disease progression. Data are observational and represent associations and causality cannot be inferred. Despite 
these limitations, our study has identified 4 high value biomarkers of which urinary CTXII may be considered 
as clinically useful for investigation of OA.
In conclusion, of the 19 biomarkers analysed urinary CTXII, serum COMP, CS846 and Coll2-1 NO2 appear 
to be the most promising biomarkers for OA as they relate to both structural damage as well as symptoms in knee 
OA. These markers do not correlate with each other but when combined the AUC values improved compared 
to that of the single biomarker. Our data show that Urinary CTXII had the strongest and consistent associations 
with clinical symptoms of OA as well as radiographic evidence of joint damage suggesting that urinary CTXII 
is the best-qualified biomarker for evaluation of OA. We suggest that urinary CTXII may be a clinically useful 
Figure 3.  Receiver operating characteristic curves for combined biomarkers: CS846, COMP, Coll2-1 NO2 and 
urinary CTXII. The data was adjusted to age, BMI, gender and race. The diagonal segment is the reference line.
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biomarker and it would be highly relevant for care planning and for development of disease modifying drugs 
for this very common condition.
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